Vindesine, also termed Eldisine, is a semisynthetic vinca alkaloid derived from the flowering plant Catharanthus roseus. Like the natural and semisynthetic vinca alkaloids derived from this plant, vindesine is an inhibitor of mitosis that is used as a chemotherapeutic agent that binds to tubulin and inhibits microtubule polymerization, producing metaphase arrest and subsequent apoptotic cell death in dividing tumor cells. It is prepared by chemical modification of the natural bisindole framework and is administered intravenously most often as the sulfate salt; the molecule contains multiple stereocenters, indole and vindoline-derived substructures, ester and tertiary amine functional groups, and requires controlled formulation and handling because of low therapeutic index and cytotoxic potency.
Parent: Vincristine / Vindesine
Related substances for vindesine are monitored by validated chromatographic methods and typically include unreacted precursors and structural analogs such as vinblastine and other bisindole alkaloids, vindoline and catharanthine fragments, N-oxide variants, deacetyl and desmethyl degradants, and minor stereoisomeric or hydrolysis products. Typical manufacturer specifications and quality control practices aim to keep individual known related compounds at or below approximately 0.5 to 1.0 percent area by HPLC and total related compounds below approximately 2.0 to 3.0 percent area by HPLC, with unspecified impurities reported and investigated at lower thresholds such as 0.1 percent. Residual solvents, inorganic counterions and degradation products are controlled to pharmacopeial or regulatory limits appropriate for parenteral cytotoxic agents, and stability studies guide allowable impurity profiles during shelf life.
Vindesine is used as a cytotoxic chemotherapeutic agent in oncology regimens, most commonly for certain hematologic malignancies and solid tumors. It is used alone or in combination protocols for indications such as acute lymphoblastic leukemia, various lymphomas, and selected lung and breast cancers, where its antimitotic activity helps reduce rapidly dividing malignant cell populations. Clinical use requires specialist oversight because of dose-limiting toxicities including myelosuppression and neurotoxicity.
Vindesine is a complex bisindole alkaloid derived from coupling of catharanthine and vindoline-type cores, giving a multi-ring structure with multiple chiral centers. Key structural features include indole rings, ester linkages, hydroxyl functionalities and a tertiary amine; these create the three-dimensional scaffold responsible for tubulin binding. The drug is typically formulated as a sulfate salt for intravenous administration.
